Patient Selection
A baseline PET scan with VisAcT® can help determine if a patient is immune-ready for immunotherapy or if immune priming is needed before starting treatment.
Therapy Response
VisAcT® PET scans performed early in the treatment may help assess whether a patient’s immune system is responding effectively to immunotherapy.
Assessment of Immune-related Adverse Effects
An on-treatment VisAcT® scan may reveal cytotoxic T cell accumulation in off-target tissues, allowing timely interventions and prevention of severe adverse events.
Neuroinflammation
Neuroinflammation contributes to the progression and severity of neurodegenerative conditions such as multiple sclerosis, Alzheimer’s and Parkinson’s diseases. Imaging neuroinflammation is crucial for understanding neurological disorders, developing targeted treatments and improving patient outcomes.
Cardiac Imaging
VisAcT® can assess mitochondrial function in cardiomyocytes enabling early detection of cardiotoxicity and assessment of myocardial viability.